ATE257485T1 - Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung - Google Patents

Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung

Info

Publication number
ATE257485T1
ATE257485T1 AT97946328T AT97946328T ATE257485T1 AT E257485 T1 ATE257485 T1 AT E257485T1 AT 97946328 T AT97946328 T AT 97946328T AT 97946328 T AT97946328 T AT 97946328T AT E257485 T1 ATE257485 T1 AT E257485T1
Authority
AT
Austria
Prior art keywords
vegf
variant
variants
growth factor
vascular endothelial
Prior art date
Application number
AT97946328T
Other languages
English (en)
Inventor
Bruce A Keyt
Francis Hung Nguyen
Napoleone Ferrara
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE257485T1 publication Critical patent/ATE257485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97946328T 1996-10-17 1997-10-10 Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung ATE257485T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/734,443 US6750044B1 (en) 1996-10-17 1996-10-17 Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
PCT/US1997/019471 WO1998016551A2 (en) 1996-10-17 1997-10-10 Variants of vascular endothelial cell growth factor having antagonistic properties

Publications (1)

Publication Number Publication Date
ATE257485T1 true ATE257485T1 (de) 2004-01-15

Family

ID=24951725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946328T ATE257485T1 (de) 1996-10-17 1997-10-10 Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung

Country Status (11)

Country Link
US (3) US6750044B1 (de)
EP (1) EP0931092B1 (de)
JP (2) JP2000507456A (de)
AT (1) ATE257485T1 (de)
AU (1) AU718327B2 (de)
CA (1) CA2267661C (de)
DE (1) DE69727149T2 (de)
DK (1) DK0931092T3 (de)
ES (1) ES2214640T3 (de)
PT (1) PT931092E (de)
WO (1) WO1998016551A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
DK1140173T4 (da) * 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
ATE420177T1 (de) * 1999-04-16 2009-01-15 Genentech Inc Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen
US7090834B1 (en) 1999-04-16 2006-08-15 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
AU5023300A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor variants
WO2001012809A2 (en) * 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
WO2002081520A2 (en) * 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Single chain dimeric polypeptides derived from the vegf family
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
EP1578801A2 (de) * 2002-12-27 2005-09-28 Domantis Limited Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
HRP20120845T1 (hr) 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
DK1773884T3 (da) 2004-08-03 2012-05-21 Innate Pharma Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
AR062069A1 (es) 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
EP2068877A4 (de) 2006-07-19 2011-09-21 Cleveland Clinic Foundation Verbindungen und verfahren zur modulierung von angiogenese
DK2457929T3 (en) * 2006-10-04 2016-09-05 Genentech Inc Elisa vegf
WO2008059052A1 (en) 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
EP2323679A4 (de) 2008-07-25 2012-08-22 Univ Colorado Clip-hemmer und verfahren zur modulierung der immunfunktion
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
RU2668174C2 (ru) 2012-07-30 2018-09-26 Трофоген Инк. Суперагонисты гликопротеинового гормона длительного действия
CN105873602A (zh) 2013-11-05 2016-08-17 特洛佛根股份有限公司 糖蛋白激素长效超激动剂
EP3216458A1 (de) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
EP3576726A1 (de) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Verfahren und produkte in verbindung mit glutaminase-hemmern
BR112020022294A2 (pt) 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
CN114606240B (zh) * 2022-03-15 2023-05-09 暨南大学 特异性识别血管内皮生长因子的核酸适配体及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5008196A (en) 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5008195A (en) * 1988-08-05 1991-04-16 Uop Some novel producers of cyclodextrin glycosyltransferases
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
EP0566673A1 (de) * 1990-12-21 1993-10-27 Creative Biomolecules, Inc. Biosynthetische pdgf-antagonisten
DE69232718T2 (de) 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
CA2158745C (en) 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor

Also Published As

Publication number Publication date
DE69727149T2 (de) 2004-10-28
US20040152636A1 (en) 2004-08-05
EP0931092B1 (de) 2004-01-07
JP2000507456A (ja) 2000-06-20
JP2004339233A (ja) 2004-12-02
PT931092E (pt) 2004-05-31
CA2267661C (en) 2005-08-23
US20070238659A1 (en) 2007-10-11
DK0931092T3 (da) 2004-05-17
AU718327B2 (en) 2000-04-13
WO1998016551A2 (en) 1998-04-23
US6750044B1 (en) 2004-06-15
CA2267661A1 (en) 1998-04-23
AU5152398A (en) 1998-05-11
ES2214640T3 (es) 2004-09-16
WO1998016551A3 (en) 1998-05-28
DE69727149D1 (de) 2004-02-12
EP0931092A2 (de) 1999-07-28

Similar Documents

Publication Publication Date Title
ATE257485T1 (de) Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung
Kovacina et al. Interactions of recombinant and platelet transforming growth factor-β1 precursor with the insulin-like growth factor II/mannose 6-phosphate receptor
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
US20110076234A1 (en) Peptides comprising an isodgr motif
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
NO304267B1 (no) AnalogifremgangsmÕte for fremstilling av en terapeutisk aktiv spesifikk blodplateaggregasjonsinhibitor (PAI) peptid
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
ZA943464B (en) Vascular endothelial growth factor 2
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
EP0577605A4 (de)
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
WO2000047740A3 (en) Tnf-related proteins
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
NL8921262A (nl) Neutrofiel-activerend peptide-2, werkwijzen voor het bereiden van deze factor en preparaten die dit peptide bevatten.
Palaszynski Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
LV11816A (lv) Implantejama zalu forma
EP1456239A4 (de) Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne
ATE266722T1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
ATE226250T1 (de) Polypeptide und peptide dafür kodierende nukleinsaüre und ihre verwendung im zusammenhang mit tumortherapie, entzündung oder immunology
Lillquist et al. Structure-activity studies of human IL-1 beta with mature and truncated proteins expressed in Escherichia coli.
DE3851226D1 (de) Wachstumsfaktor-rezeptor.
KR940007059A (ko) 변형된 혈소판 인자-4
Zuberi et al. Production of IL-1-mimicking anti-idiotypic antibodies in rabbits in response to IL-1 immunization

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0931092

Country of ref document: EP